EP News Bureau

First course from Jan 16-25, last date to apply extended to December 30

A QuintilesIMS report finds that complex generics is a lucrative market for drug manufacturers, but only if they can adapt to a…

The relatively strong growth will primarily be driven by the increase in diagnosed prevalent cases

Growth will not be aided by the weak anti-hypertensive pipeline, due to lack of innovative products in late-stage development

Russia-based Biosintez focuses on the hospital segment with annual revenues of about $52 million for 2015

Featuring - Jawed Zia, Novartis India - Mike Warmuth, Abbott - Daara Patel, IDMA - Dr Ajit Dangi, Danssen Consulting - Utkarsh…

Jawed Zia, Country President, Novartis India, advises pharma leaders to constantly evaluate their skills and course correct to…

India was among the first countries in which Abbott expanded outside the US, way back in 1910. Today, more than 85 per cent of…

Dr Ajit Dangi, President & CEO Danssen Consulting, shares his tips for pharma leaders to operate and thrive in a VUCA world…

Utkarsh Palnitkar, Partner, National Head – Infrastructure, Government & Healthcare National Head – Life Sciences practice,…